XOMA, Aragen Bioscience collaborate
XOMA and Aragen Bioscience have entered into an agreement under which Aragen Bioscience will provide its clients access to XOMA’s proprietary Human Engineering technology for antibody humanization. Financial terms were not disclosed.
The Human Engineering technology enables the derivation of humanized variable region amino acid sequences from mature mouse variable region amino acid sequences. “Access to XOMA’s extensive technology and expertise in antibody humanization allows Aragen Bioscience to provide its customers a seamless transition from murine antibody discovery and sequencing to antibody testing, variable domain humanization, stable and transient expression, cell line development and pre-clinical production services. The addition of XOMA’s technology to our services enables our clients to quickly access antibody humanization technology that is recognized throughout the industry as cutting-edge,” commented Aragen Bioscience’s president and CEO, Rick Srigley.
“We believe that pairing our Human Engineering technology and know-how with Aragen Bioscience’s cell line development experience and expertise is an excellent way to make this technology available to the pharmaceutical and biotech industries,” said Patrick J. Scannon, M.D., Ph.D., executive vice president and chief scientific officer at XOMA.